drugset / Trial / NCT07138001
Phase 2 Clinical Trial of KH617
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma
Timeline
- Start
- 2025-08
- Primary completion
- 2027-09
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Carboplatin | Small molecule | 100 mg/m2 | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | KH617 | Unknown | 33 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |